Sex: F
Vaccine: RSV
Symptoms: Exposure during pregnancy, Product use issue, Wrong product administered
Clinical narrative: pregnant women were mistakenly given the alternative vaccine Arexvy instead of Abrysvo; pregnant women were mistakenly given the alternative vaccine Arexvy instead of Abrysvo; This non-serious prospective pregnancy case was reported by a consumer and described the occurrence of vaccine exposure during pregnancy in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: pregnant women were mistakenly given the alternative vaccine Arexvy instead of Abrysvo) and wrong vaccine administered (Verbatim: pregnant women were mistakenly given the alternative vaccine Arexvy instead of Abrysvo). The outcome of the vaccine exposure during pregnancy and wrong vaccine administered were unknown.   Pregnancy exposure: Pregnancy Exposure (Arexvy): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing   Additional Information: GSK Receipt Date: 14-FEB-2024 and 22-FEB-2024 The reporter stated this winter there were two vaccines available to ward off respiratory syncytial virus, which was particularly dangerous to older adults and infants one of them was Abrysvo, made by Pfizer which was approved for pregnant women, and neither was for young children. The centers for disease control and prevention reported that the mistake involving two vaccines used to treat RSV, a serious respiratory virus. The vaccines were approved for distribution in May neither of the vaccines, Pfizer Abrysvo made by Pfizer, and Arexvy made by GlaxoSmithKline, were listed as safe to treat children experiencing the illness and Arexvy had not been approved for pregnant women. Yet as of 17th January 2024, both were administered to 128 pregnant women and 25 babies, according to the centers for disease control and prevention, though the agency noted that these types of errors were uncommon. The centers for disease control was urging healthcare providers to be more careful and issued a report stated that 128 pregnant women and 25 babies received incorrect vaccines. The distinction was apparently slipped by some clinicians and pharmacists and at least 128 pregnant women (patients) were mistakenly given the alternative vaccine Arexvy by GlaxoSmithKline. Arexvy had not been tested in pregnant women or children, so information about its effects in those groups was limited. Yet no serious harms from the errors have been confirmed, but the outcome was unknown in most reported cases. The centers for disease control and prevention warned a pediatric infectious disease physician and an adviser to the agency. This news was relative to the estimated one million infants protected from the centers for disease control and prevention stated RSV either by nirsevimab, an immunization recommended for infants younger than 8 months born during RSV season, or through the vaccination of pregnant people. The centers for disease control and prevention stated those reported to had received the unapproved vaccines did not have serious side effects. The pregnant patient received Arexvy vaccine instead of alternative Abrysvo vaccine, which led to wrong vaccine administered and vaccine exposure during pregnancy. The consent to follow up requested. This case was 1 of 128 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR020863:same reporter US-GSK-US2024AMR020864:same reporter US-GSK-US2024AMR024895:Master case US-GSK-US2024AMR024888:Master case US-GSK-US2024AMR024894:Master case US-GSK-US2024AMR024890:Master case US-GSK-US2024AMR024896:Master case US-GSK-US2024AMR024893:Master case US-GSK-US2024AMR024891:Master case US-GSK-US2024AMR024892:Master case US-GSK-US2024AMR024889:master case